IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 21.53

Change

0.00 (0.00)%

Market Cap

USD 0.12B

Volume

0.12M

Analyst Target

N/A
Analyst Rating

Sell

ducovest Verdict
Created with Highstock 5.0.6

Very Bearish

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
IDNA VTI
  • VTI
Relative Returns (From:    To: 2025-03-22 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.55 (+0.38%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+0.53 (+0.77%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+1.46 (+1.40%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+1.87 (+2.25%)

USD 0.18B
SBIO ALPS Medical Breakthroughs ETF

+0.50 (+1.64%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+1.77 (+1.83%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.55 (+1.94%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.27 (+2.09%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.48 (+2.46%)

USD 0.01B
IHF iShares U.S. Healthcare Provid..

+0.57 (+1.10%)

N/A

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.86% 19% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.86% 19% F 28% F
Trailing 12 Months  
Capital Gain -9.92% 14% F 22% F
Dividend Return 0.46% 44% F 6% D-
Total Return -9.45% 14% F 19% F
Trailing 5 Years  
Capital Gain -9.97% 10% F 13% F
Dividend Return 3.83% 53% F 6% D-
Total Return -6.14% 10% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -8.55% 5% F 8% B-
Dividend Return -8.00% 5% F 7% C-
Total Return 0.56% 53% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 27.25% 14% F 36% F
Risk Adjusted Return -29.34% 5% F 10% F
Market Capitalization 0.12B 60% D- 29% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.